Bacterial undecaprenyl pyrophosphate–dependent cell wall synthesis pathway (UPP pathway)

The bacterial undecaprenyl pyrophosphate–dependent cell wall synthesis pathway is a fundamental metabolic route essential for the assembly of the bacterial cell envelope. It centers on the 55-carbon isoprenoid lipid carrier, undecaprenyl phosphate (UP), also known as bactoprenol, which transports hydrophilic cell wall precursors across the cytoplasmic membrane (nih.gov, 2024; wikipedia.org, 2024). The pathway involves the de novo synthesis of undecaprenyl pyrophosphate (UPP) by the enzyme undecaprenyl pyrophosphate synthase (UppS), its subsequent dephosphorylation to UP, and the recycling of UPP back to UP after each round of polymer synthesis (nih.gov, 2021; frontiersin.org, 2019). This cycle is vital for the production of peptidoglycan, teichoic acids, and O-antigens, making it a cornerstone of bacterial survival and structural integrity (asm.org, 2024; brownlab.ca, 2015). As this pathway is absent in humans and highly conserved across bacterial species, it serves as a major target for antibiotic therapy. Classic antibiotics like bacitracin disrupt the pathway by sequestering UPP and preventing its recycling, while newer agents like teixobactin target the lipid-linked intermediates (nih.gov, 2024; pnas.org, 2024). Inhibition of any step in this cycle leads to the depletion of the available lipid carrier pool, halting cell wall construction and resulting in bacterial cell death through osmotic lysis (patsnap.com, 2024). Ongoing research focuses on targeting specific enzymes within the pathway, such as UppS and BacA, to develop novel antimicrobial agents capable of overcoming multi-drug resistance (acs.org, 2021; nih.gov, 2020).

Other names

C55-isoprenyl pyrophosphate pathwayBactoprenol pathwayLipid II cycleUndecaprenyl phosphate recycling pathwayC55-PP pathwayUndecaprenyl phosphate biosynthetic process

Inhibition of bacterial cell wall synthesis through the sequestration of lipid carriers (undecaprenyl pyrophosphate or undecaprenyl phosphate), inhibition of de novo lipid carrier synthesis (UppS inhibition), or blockade of carrier recycling via phosphatase inhibition (BacA/UppP inhibition).